Studies demonstrate that PD-1/PD-L1 inhibitors enhance T cell antitumor activity by blocking tumor immune escape mechanisms, achieving objective response rates of approximately 15% to 30% in advanced bladder cancer patients [12]. Here, CD274 is linked to neoplasm.